6 News & Press Releases found
Kiadis Pharma NV News
-
Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings
The Offeror, Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis today announce that the conversion of Kiadis from a public limited liability company (naamloze vennootschap) into a private limited liability company (besloten vennootschap met ...
-
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer During the Post-Closing Acceptance Period, approximately 2.35% of the Shares on a Fully Diluted basis were tendered under the ...
-
Sanofi completes Kiadis acquisition
Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and Brussels: KDS) today jointly announce the successful completion of Sanofi’s acquisition of Kiadis, a clinical-stage biopharmaceutical company developing next ...
-
Sanofi declares the Offer for Kiadis unconditional
Sanofi declares the Offer for Kiadis unconditional 95.03% of Kiadis shares in total committed under the Offer 95.03% of the Shares on a Fully Diluted basis have been tendered or irrevocably committed to be delivered to Sanofi at settlement of the ...
-
Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) announces that all resolutions related to the recommended public offer by Sanofi have been adopted at the extraordinary general ...
-
Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) today announces that it has issued ordinary shares to Kreos Capital V (UK) Limited (“Kreos Capital”). This ...